Volume 31, Issue 145 (March & April 2023)                   J Adv Med Biomed Res 2023, 31(145): 133-143 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi Moghaddam Z, Ekrami B, Asaadi Tehrani G. CXCL12/CXCR4 Gene Polymorphism as a Putative Prognostic Factor for Metastasizing Breast Cancer Under Chemotherapy. J Adv Med Biomed Res 2023; 31 (145) :133-143
URL: http://journal.zums.ac.ir/article-1-6763-en.html
CXCL12/CXCR4 Gene Polymorphism as a Putative Prognostic Factor for Metastasizing Breast Cancer Under Chemotherapy
Zhaleh Karimi Moghaddam1 , Bahareh Ekrami2 , Golnaz Asaadi Tehrani 3
1- Dept. of Radiation Oncology,Vali-e-Asr Hospital,School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2- Dept. of Genetics, Faculty of Sciences, Zanjan Branch, Islamic Azad University, Zanjan, Iran
3- Dept. of Genetics, Faculty of Sciences, Zanjan Branch, Islamic Azad University, Zanjan, Iran , Drgolnazasaadi@gmail.com
Abstract:   (10743 Views)

Background and Objective: C-X-C motif chemokine ligand 12 (CXCL12; known as stromal cell-derived factor 1 [SDF-1]) and its receptor C-X-C chemokine receptor 4 (CXCR4) are 2 pairs studied in breast cancer metastasis. This study aimed to investigate the relationship between the occurrence of CXCL4 and CXCL12 gene polymorphisms and the clinical and pathological characteristics of patients with metastatic breast cancer under chemotherapy.
Materials and Methods: Genomic DNA was extracted from the blood samples of 30 patients with metastatic breast cancer and 30 control samples. The polymorphisms of CXCL12 and CXCR4 were detected using the tetra-primer amplification refractory mutation system–polymerase chain reaction (T-ARMS–PCR) method. The results were analyzed using SPSS version 20 with a 95% CI.
Results: The mean age of the patients was 50 years, and the average age of the healthy subjects was 41.23 years. The disease was diagnosed in 63.33% of the cases before menopause and in 36.66% after menopause. Also, 73.32% of patients showed metastatic signs 3-6 years after primary chemotherapy, and 63.33% of all patients had a grade III tumor. There was a significant relationship between the time of relapse after chemotherapy and the occurrence of polymorphisms (P = 0.001), between age and incidence (P = 0.02), and between menopausal age and incidence (P = 0.07).
Conclusion: No significant correlation was found between the occurrence of mutant alleles of CXCL12 and CXCR4 polymorphisms and breast cancer. The relapse of the disease after chemotherapy and the age of menopause are associated with the occurrence of polymorphisms. However, further studies are needed to confirm the results.

Keywords: Breast cancer, Metastasis, Chemotherapy, CXCL12, CXCR4
Full-Text [PDF 460 kb]   (7840 Downloads) |   |   Full-Text (HTML)  (693 Views)  

✅No significant correlation was found between the occurrence of mutant alleles of CXCL12 and CXCR4 polymorphisms and breast cancer. The relapse of the disease after chemotherapy and the age of menopause are associated with the occurrence of polymorphisms. However, further studies are needed to confirm the results.


Type of Study: Original Article | Subject: Clinical medicine
Received: 2022/01/22 | Accepted: 2022/09/20 | Published: 2023/03/13
References
1. Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Res. 2020;22(1):118. [DOI:10.1186/s13058-020-01343-1] [PMID] [PMCID]
2. da Costa Vieira RA, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. Clinics (Sao Paulo). 2017;72(4):244-53. [DOI:10.6061/clinics/2017(04)09]
3. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res. 2009;15(9):2962-70. [DOI:10.1158/1078-0432.CCR-08-2495] [PMID]
4. Samarendra H, Jones K, Petrinic T, et al. A meta-analysis of CXCL12 expression for cancer prognosis. Br J Cancer. 2017;117(1):124-35. [DOI:10.1038/bjc.2017.134] [PMID] [PMCID]
5. Parkes EE, Walker SM, Taggart LE, et al. Activation of sting-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109(1). [DOI:10.1093/jnci/djw199] [PMID] [PMCID]
6. Scala S. Molecular Pathways: Targeting the CXCR4-CXCL12 axis--untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21(19):4278-85. [DOI:10.1158/1078-0432.CCR-14-0914] [PMID]
7. Lee SY, Kim EK, Seo HB, et al. IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 Pathway. Inflammation. 2020;43(2):664-72. [DOI:10.1007/s10753-019-01148-1] [PMID] [PMCID]
8. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-13. [DOI:10.1182/blood-2016-04-709519] [PMID] [PMCID]
9. Takano T, Li YJ, Kukita A, et al. Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis. Lab Invest. 2014;94(3):286-96. [DOI:10.1038/labinvest.2013.152] [PMID]
10. Kobayashi K, Sato K, Kida T, et al. Stromal cell-derived factor-1alpha/C-X-C chemokine receptor type 4 axis promotes endothelial cell barrier integrity via phosphoinositide 3-kinase and Rac1 activation. Arterioscler Thromb Vasc Biol. 2014;34(8):1716-22. [DOI:10.1161/ATVBAHA.114.303890] [PMID]
11. Tong X, Ma Y, Deng H, et al. The SDF-1 rs1801157 polymorphism is associated with cancer risk: An update pooled analysis and FPRP test of 17,876 participants. Sci Rep. 2016;6:27466. [DOI:10.1038/srep27466] [PMID] [PMCID]
12. Qin LF, Qin JM, Zhang JQ, Lv XP, Huang LY, Wang JJ. CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol. 2018;14(13):1261-71. [DOI:10.2217/fon-2017-0613] [PMID]
13. Yu M, Berk R, Kosir MA. CXCL7-mediated stimulation of lymphangiogenic factors VEGF-C, VEGF-D in human breast cancer cells. J Oncol. 2010;2010:939407. [DOI:10.1155/2010/939407] [PMID] [PMCID]
14. Okuyama N, Cezar dos Santos F, Paiva Trugilo K, Brajão de Oliveira K. Involvement of CXCL12 pathway in HPV-related diseases. AIMS Med Sci. 2016, 3(4): 417-40. [DOI:10.3934/medsci.2016.4.417]
15. Saini V, Marchese A, Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem. 2010;285(20):15566-76. [DOI:10.1074/jbc.M110.103408] [PMID] [PMCID]
16. Guembarovski AL, Guembarovski RL, Hirata BKB, et al. CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer. Mol Biol Rep. 2018;45(5):741-50. [DOI:10.1007/s11033-018-4215-7] [PMID]
17. Bodelon C, Malone KE, Johnson LG, et al. Common sequence variants in chemokine-related genes and risk of breast cancer in post-menopausal women. Int J Mol Epidemiol Genet. 2013;4(4):218-27.
18. Sun Y, Mao X, Fan C, et al. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol. 2014;35(8):7765-73. [DOI:10.1007/s13277-014-1816-1] [PMID] [PMCID]
19. de Oliveira KB, Guembarovski RL, Oda JM, Mantovani MS, et al. CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine. 2011;55(2):260-5. [DOI:10.1016/j.cyto.2011.04.017] [PMID]
20. Schimanski CC, Jordan M, Schlaegel F, et al. SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer. Int J Oncol. 2011;39(2):515-20. [DOI:10.3892/ijo.2011.1044] [PMID]
21. Chen R, Xu Y, Du X, et al. CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma. Onco Targets Ther. 2015;8:2835-42. [DOI:10.2147/OTT.S90430] [PMID] [PMCID]
22. Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med. 2009;47(4):412-8. [DOI:10.1515/CCLM.2009.092] [PMID]
23. Lee YL, Kuo WH, Lin CW, et al. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer. 2011;73(2):147-52. [DOI:10.1016/j.lungcan.2010.12.011] [PMID]
24. Yazdani Z, Mousavi Z, Moradabadi A, Hassanshahi G. Significance of CXCL12/CXCR4 ligand/receptor axis in various aspects of acute myeloid leukemia. Cancer Manag Res. 2020;12:2155-65. [DOI:10.2147/CMAR.S234883] [PMID] [PMCID]
25. Falk D, Cubbin C, Jones B, Carrillo-Kappus K, Crocker A, Rice C. Increasing breast and cervical cancer screening in rural and border Texas with friend to friend plus patient navigation. J Cancer Educ. 2018;33(4):798-805. [DOI:10.1007/s13187-016-1147-6] [PMID] [PMCID]
26. Okuyama Kishima M, Brajao de Oliveira K, Ariza CB, et al. Genetic polymorphism and expression of CXCR4 in breast cancer. Anal Cell Pathol (Amst). 2015;2015:289510. [DOI:10.1155/2015/289510] [PMID] [PMCID]
27. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109-26.
28. Seymour CB, Mothersill C. Breast cancer causes and treatment: where are we going wrong? Breast Cancer (Dove Med Press). 2013;5:111-9. [DOI:10.2147/BCTT.S44399] [PMID] [PMCID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb